HYUNDAI FEED Inc (016790) - Total Liabilities

Latest as of June 2025: ₩28.17 Billion KRW ≈ $19.09 Million USD

Based on the latest financial reports, HYUNDAI FEED Inc (016790) has total liabilities worth ₩28.17 Billion KRW (≈ $19.09 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of HYUNDAI FEED Inc to assess how effectively this company generates cash.

HYUNDAI FEED Inc - Total Liabilities Trend (2015–2024)

This chart illustrates how HYUNDAI FEED Inc's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are HYUNDAI FEED Inc's assets to evaluate the company's liquid asset resilience ratio.

HYUNDAI FEED Inc Competitors by Total Liabilities

The table below lists competitors of HYUNDAI FEED Inc ranked by their total liabilities.

Company Country Total Liabilities
Nyxoah
BR:NYXH
Belgium €42.65 Million
Bellevue Group AG
SW:BBN
Switzerland CHF34.51 Million
Alpha Cognition Inc
NASDAQ:ACOG
USA $12.39 Million
Aesler Grup Internasional Tbk Pt
JK:RONY
Indonesia Rp24.40 Billion
Kyung Nong Corporation
KO:002100
Korea ₩250.09 Billion
Megaforce Co Ltd
TWO:3294
Taiwan NT$2.61 Billion
Cannara Biotech Inc
V:LOVE
Canada CA$62.63 Million
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
Turkey TL2.26 Billion

Liability Composition Analysis (2015–2024)

This chart breaks down HYUNDAI FEED Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 016790 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.77 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how HYUNDAI FEED Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for HYUNDAI FEED Inc (2015–2024)

The table below shows the annual total liabilities of HYUNDAI FEED Inc from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩28.05 Billion
≈ $19.01 Million
-84.47%
2023-12-31 ₩180.58 Billion
≈ $122.38 Million
-21.11%
2022-12-31 ₩228.90 Billion
≈ $155.12 Million
+533.27%
2021-12-31 ₩36.15 Billion
≈ $24.50 Million
-7.88%
2020-12-31 ₩39.24 Billion
≈ $26.59 Million
+3.47%
2019-12-31 ₩37.92 Billion
≈ $25.70 Million
+1.87%
2018-12-31 ₩37.23 Billion
≈ $25.23 Million
+3.12%
2017-12-31 ₩36.10 Billion
≈ $24.46 Million
-5.78%
2016-12-31 ₩38.31 Billion
≈ $25.97 Million
-41.07%
2015-12-31 ₩65.02 Billion
≈ $44.06 Million
--

About HYUNDAI FEED Inc

KQ:016790 Korea Packaged Foods
Market Cap
$126.96 Million
₩187.34 Billion KRW
Market Cap Rank
#18267 Global
#910 in Korea
Share Price
₩994.00
Change (1 day)
+0.00%
52-Week Range
₩994.00 - ₩994.00
All Time High
₩15077.70
About

HYUNDAI FEED Inc. engages in the manufacture and sale of formulated feed. Its primary products include poultry and pig feed. The company also engages in the biopharmaceutical business. In addition, it focuses on the development and commercialization of immunotherapies for cancer. Further, the company's lead product includes oregovomab, an immunotherapy for ovarian cancer. Additionally, it is invo… Read more